Cell Therapies for Acute Radiation Syndrome
International Journal of Molecular Sciences · 26.06.2024 · 25 (13) · 6973
DOI: 10.3390/ijms25136973 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 26.06.2024. Verfasst von Barbara A Christy und 5 weiteren Autor:innen. Beteiligte Einrichtung: Blood and Shock Resuscitation, US Army Institute of Surgical Research, Joint Base San Antonio, Fort Sam Houston, TX 78234, USA. Hauptthemen laut MEDLINE: Acute Radiation Syndrome. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 152 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Congressionally Directed Medical Research Programs, Congressionally Directed Medical Research Program.
Abstract (Originalsprache)
The risks of severe ionizing radiation exposure are increasing due to the involvement of nuclear powers in combat operations, the increasing use of nuclear power, and the existence of terrorist threats. Exposure to a whole-body radiation dose above about 0.7 Gy results in H-ARS (hematopoietic acute radiation syndrome), which is characterized by damage to the hematopoietic system; higher doses result in further damage to the gastrointestinal and nervous systems. Only a few medical countermeasures for ARS are currently available and approved for use, although others are in development. Cell therapies (cells or products produced by cells) are complex therapeutics that show promise for the treatment of radiation injury and have been shown to reduce mortality and morbidity in animal models. Since clinical trials for ARS cannot be ethically conducted, animal testing is extremely important. Here, we describe cell therapies that have been tested in animal models. Both cells and cell products appear to promote survival and lessen tissue damage after whole-body irradiation, although the mechanisms are not clear. Because radiation exposure often occurs in conjunction with other traumatic injuries, animal models of combined injury involving radiation and future countermeasure testing for these complex medical problems are also discussed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Blood and Shock Resuscitation, US Army Institute of Surgical Research, Joint Base San Antonio, Fort Sam Houston, TX 78234, USA.
- Department of Molecular Medicine, UT Health San Antonio, San Antonio, TX 78229, USA.
- Hemorrhage and Vascular Dysfunction, US Army Institute of Surgical Research, Joint Base San Antonio, Fort Sam Houston, TX 78234, USA.
- Department of Surgery, UT Health San Antonio, San Antonio, TX 78229, USA.
- Trauma Research and Combat Casualty Care Collaborative, UT Health San Antonio, San Antonio, TX 78229, USA.
ORCID-Profile: Maryanne C Herzig, Arezoo Mohammadipoor
Förderung
- Congressionally Directed Medical Research Programs
- Congressionally Directed Medical Research Program
Zitieren
APA
Christy, B. A., Herzig, M. C., Wu, X., Mohammadipoor, A., McDaniel, J. S., & Bynum, J. A. (2024). Cell Therapies for Acute Radiation Syndrome. International Journal of Molecular Sciences, 25(13), 6973. https://doi.org/10.3390/ijms25136973
Vancouver
Christy BA, Herzig MC, Wu X, Mohammadipoor A, McDaniel JS, Bynum JA. Cell Therapies for Acute Radiation Syndrome. International Journal of Molecular Sciences. 2024;25(13):6973. doi:10.3390/ijms25136973
BibTeX
@article{Christy2024,
author = {Christy, Barbara A and Herzig, Maryanne C and Wu, Xiaowu and Mohammadipoor, Arezoo and McDaniel, Jennifer S and Bynum, James A},
title = {Cell Therapies for Acute Radiation Syndrome},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {13},
pages = {6973},
doi = {10.3390/ijms25136973}
}
EUVIMED